【レポートの概要（一部）】
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 9
Global Markets Direct Report Coverage 9
Fallopian Tube Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Fallopian Tube Cancer – Overview 11
Pipeline Products for Fallopian Tube Cancer – Comparative Analysis 12
Fallopian Tube Cancer – Therapeutics under Development by Companies 13
Fallopian Tube Cancer – Therapeutics under Investigation by Universities/Institutes 18
Fallopian Tube Cancer – Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Fallopian Tube Cancer – Products under Development by Companies 22
Fallopian Tube Cancer – Products under Investigation by Universities/Institutes 27
Fallopian Tube Cancer – Companies Involved in Therapeutics Development 28
AbbVie Inc. 28
Acceleron Pharma, Inc. 29
Adaptimmune Limited 30
Amgen Inc. 31
Array BioPharma Inc. 32
Astex Pharmaceuticals, Inc. 33
AstraZeneca PLC 34
Bayer AG 35
BioMarin Pharmaceutical Inc. 36
Bionomics Limited 37
Boehringer Ingelheim GmbH 38
Celldex Therapeutics, Inc. 39
Celsion Corporation 40
Cerulean Pharma, Inc. 41
Clovis Oncology, Inc. 42
Corcept Therapeutics Incorporated 43
CTI BioPharma Corp. 44
Curis, Inc. 45
Eli Lilly and Company 46
Exelixis, Inc. 47
F. Hoffmann-La Roche Ltd. 48
Galena Biopharma, Inc. 49
Genentech, Inc. 50
GlaxoSmithKline plc 51
Glycotope GmbH 52
Gradalis Inc. 53
ImmunoGen, Inc. 54
Immunotope, Inc. 55
Immunovaccine, Inc. 56
Johnson & Johnson 57
Karyopharm Therapeutics, Inc. 58
Lee’s Pharmaceutical Holdings Limited 59
MabVax Therapeutics Holdings, Inc. 60
MedImmune, LLC 61
Merck & Co., Inc. 62
Merrimack Pharmaceuticals, Inc. 63
Millennium Pharmaceuticals, Inc. 64
NeoStem, Inc. 65
Novartis AG 66
Oasmia Pharmaceutical AB 67
OBI Pharma, Inc. 68
Oncolytics Biotech Inc. 69
OncoMed Pharmaceuticals, Inc. 70
Onxeo SA 71
Oxford BioMedica plc 72
OXiGENE, Inc. 73
Pharma Mar, S.A. 74
Pharmacyclics, Inc. 75
PsiOxus Therapeutics, Ltd. 76
Recepta Biopharma S.A. 77
Sanofi Pasteur SA 78
Sotio a.s. 79
Synta Pharmaceuticals Corp. 80
TapImmune Inc. 81
Tesaro, Inc. 82
TetraLogic Pharmaceuticals 83
TRACON Pharmaceuticals, Inc. 84
VentiRx Pharmaceuticals, Inc. 85
Fallopian Tube Cancer – Therapeutics Assessment 86
Assessment by Monotherapy Products 86
Assessment by Target 87
Assessment by Mechanism of Action 91
Assessment by Route of Administration 94
Assessment by Molecule Type 96
Drug Profiles 98
abexinostat hydrochloride – Drug Profile 98
abiraterone acetate – Drug Profile 100
ABT-767 – Drug Profile 103
alisertib – Drug Profile 104
anetumab ravtansine – Drug Profile 108
AZD-1775 – Drug Profile 110
AZD-2014 – Drug Profile 112
AZD-5363 – Drug Profile 114
belinostat – Drug Profile 116
bevacizumab – Drug Profile 119
binimetinib – Drug Profile 124
birinapant – Drug Profile 128
BNC-105P – Drug Profile 131
cabozantinib s-malate – Drug Profile 133
Cancer Stem Cell Therapy – Drug Profile 136
CDX-1401 – Drug Profile 137
Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology – Drug Profile 139
Cell Therapy to Target WT1 for Cancer – Drug Profile 141
CRLX-101 – Drug Profile 142
CUDC-427 – Drug Profile 144
dalantercept – Drug Profile 145
DCVAC/OvCa – Drug Profile 147
demcizumab – Drug Profile 148
Dendritic Cell Therapy for Ovarian, Peritoneal and Fallopian Tube Cancer – Drug Profile 152
DMUC-4064A – Drug Profile 153
DPX-Survivac – Drug Profile 154
EGEN-001 – Drug Profile 157
elesclomol – Drug Profile 159
enadenotucirev – Drug Profile 161
erismodegib – Drug Profile 163
fosbretabulin tromethamine – Drug Profile 166
GALE-301 – Drug Profile 170
ganetespib – Drug Profile 172
gimatecan – Drug Profile 176
guadecitabine – Drug Profile 178
IMGN-853 – Drug Profile 181
IMT-1012 – Drug Profile 182
ipafricept – Drug Profile 183
LCL-161 – Drug Profile 185
lifastuzumab vedotin – Drug Profile 187
LY-2606368 – Drug Profile 189
mifepristone – Drug Profile 190
MK-2206 – Drug Profile 193
motolimod – Drug Profile 196
nintedanib – Drug Profile 198
niraparib – Drug Profile 202
NSC-748933 – Drug Profile 204
OBI-822/821 – Drug Profile 205
olaratumab – Drug Profile 207
paclitaxel – Drug Profile 209
paclitaxel poliglumex – Drug Profile 211
PankoMab-GEX – Drug Profile 215
pazopanib hydrochloride – Drug Profile 216
pelareorep – Drug Profile 221
ralimetinib mesylate – Drug Profile 226
ramucirumab – Drug Profile 227
RebmAb-100 – Drug Profile 232
regorafenib – Drug Profile 234
rucaparib phosphate – Drug Profile 237
selinexor – Drug Profile 240
seribantumab – Drug Profile 244
SG-2000 – Drug Profile 247
talazoparib – Drug Profile 249
TPIV-200 – Drug Profile 252
trabectedin – Drug Profile 254
TRC-105 – Drug Profile 258
trebananib – Drug Profile 260
TroVax – Drug Profile 263
Vaccine for cancer – Drug Profile 266
Vaccine for Oncology – Drug Profile 268
varlilumab – Drug Profile 269
vCP-2292 – Drug Profile 271
X-82 – Drug Profile 273
Fallopian Tube Cancer – Recent Pipeline Updates 275
Fallopian Tube Cancer – Dormant Projects 417
Fallopian Tube Cancer – Discontinued Products 419
Fallopian Tube Cancer – Product Development Milestones 420
Featured News & Press Releases 420
Appendix 426
Methodology 426
Coverage 426
Secondary Research 426
Primary Research 426
Expert Panel Validation 426
Contact Us 426
Disclaimer 427
【レポート販売概要】
■ タイトル：卵管がん(Fallopian Tube Cancer)：治療薬開発パイプライン動向（2015年上半期版）■ 英文：Fallopian Tube Cancer - Pipeline Review, H1 2015
■ 発行日：2015年3月19日
■ 調査会社：Global Markets Direct
■ 商品コード：GMDHC6248IDB
■ 調査対象地域：グローバル
- 発電業界のM&A及び投資動向（月別）：July 2013Power Monthly Deal Analysis - July 2013: M&A and Investment Trends Summary GlobalData's “Power Monthly Deal Analysis - July 2013: M&A and Investment Trends” report is an essential source of data and trend analysis on the mergers and acquisitions (M&As) and financings in the power industry. The report provides detailed information on M&As, equity/debt offerings, private equity, venture financing an …
- 遺伝子治療の世界市場：研究開発および売上予測2016-2026Gene Therapies – Discover Revenue Predictions and See How Treating Cancer, Cardiovascular Disorders and Other Chronic Diseases Progresses What does the future hold for gene therapy? What progress and sales are possible? Avoid struggles to gain that business data. Instead find the best places for expanding revenues, also understanding trends, technologies, therapies and opportunities. Visiongain’s …
- 繊維染料の世界市場予測（～2024年）The textile dyes market is projected to register a CAGR of 5.9%, in terms of value, between 2019 and 2024.The textile dyes market is projected to grow from USD 8.2 billion in 2019 to USD 10.9 billion by 2024, at a CAGR of 5.9%, between 2019 and 2024. APAC is the largest consumer of textile dyes. Low-cost of manufacturing in APAC countries and high demand for textile dyes in the region are driving …
- Linn Energy, LLC：石油・ガスの開発・生産動向及びコスト分析– Q1, 2013Linn Energy, LLC Oil & Gas Exploration and Production Operations and Cost Analysis – Q1, 2013 Summary Linn Energy, LLC Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key o …
- 上肢痙縮：治療薬の治験動向（2014年下半期）Upper Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Upper Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014" provides data on the Upper Limb Muscle Spasticity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Upper Limb Muscle Spasticity. It includes an overview …
- 世界のラテックス・マットレス市場動向（2014～2018）TechNavio's analysts forecast the Global Latex Mattress market to grow at a CAGR of 14.87 percent over the period 2014-2018. One of the key factors contributing to this market growth is the need for environment-friendly products. The Global Latex Mattress market has also been witnessing the product innovation through R&D activities. However, the high cost of latex mattresses could pose a challenge …
- Acute Myeloid Leukemia (AML)：市場分析及び予測（～2017）OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017 Summary Acute myeloid (myelogenous, myelocytic) leukemia is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. AML is a heterogeneous disease, and many subtypes have been identified. The current standard of care consists of cy …
- 世界の商用ヘリコプタ市場動向2013-2023：市場規模及び成長要因The global commercial helicopter sector is expected to experience a growth of 2.39% during the forecast period which is primarily attributed to the growth in several sectors worldwide including offshore oil and gas exploration and production, HEMS, VIP transport, law enforcement and public safety etc.
- モーターコントロールセンター（MCC）の世界市場動向・予測（～2021）The global motor control centers market is projected to grow at a CAGR of 5.3% from 2016 to 2021, to reach a size of USD 5.83 Billion by 2021. This growth is attributed to increasing demand for industrial automation and growing concerns for energy efficiency across major industries. On the basis of end-user industry, the report segments motor control centers market into commercial and industrial. …
- 施肥潅漑および薬品混入灌漑の世界市場動向・予測（～2020）The global market for fertigation & chemigation has grown exponentially in the last few years. In terms of value, the market is projected to reach USD 42.2 Billion by 2020, at a CAGR of around 6.3% from 2015 to 2020. Water-scarce regions and agriculture-based countries are the primary targets of the industry. Factors such as increasing population & the resultant food demand and increasing water sc …
- 再生カーボンブラック（RCB）の世界市場展望2017-2026According to Stratistics MRC, the Global Recovered Carbon Black Market is accounted for $40.34 million in 2017 and is expected to reach $1,815.26 million by 2026 growing at a CAGR of 52.6% during the forecast period. Some of the key factors influencing the market growth include abundant availability of ELTS, the raw material for rCB production, growing environmental concern towards low carbon foot …
- 自動車ポリッシャーの世界市場2017-2021About Automotive Polishing Machines The automotive sales have improved worldwide. With the increase in consumers' confidence in various economies, such as the US, the automotive sales in terms of the units sold have improved. In 2017, the largest automotive market, China accounted for 24.9 million units, which are over 27% of the global automotive sales in 2015. In China, the massive population al …
- ドアストップの世界市場About Door Stops A door stop is used to hold a door open or closed. It is also used to prevent the door from opening too widely and damaging from nearby walls. A door stop can be a thin slat built inside a door from swinging through when closed. TechNavio's analysts forecast the Global Door Stop market to grow at a CAGR of 6.69 percent and 6.92 percent, respectively, in terms of revenue and unit s …
- ヘルスケア/医療分析ソリューションの世界市場The healthcare analytics market is categorized on the basis of type, component, delivery model, application, end user, and region. Factors such as the rising pressure to curb healthcare costs, big data in healthcare, technological advancements, growing awareness about benefits of analytics, and increase in venture capital investments are driving market growth. On the other hand, the operational ga …
- 世界の心臓欠損閉鎖機器（先天性心臓病(CHD)治療）市場（2014-2018）About Heart Defect Closure Devices Heart defect closure devices are used for the treatment of several CHDs. The heart closure devices help when closing the ostium/ hole/ deficiency in the structure of the heart present in the septal walls or blood vessels that occurs in the patients with CHDs. CHD is an anomaly in the structure of the heart present at the time of birth, which are among the most co …
